CAPTRUST Financial Advisors
CNCE

CAPTRUST Financial Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,394
Closed -$6K – 4494
2022
Q2 		$6K Hold
1,394
– – ﹤0.01% 4034
2022
Q1 		$5K Sell
1,394
-99
-7% -$314 ﹤0.01% 4196
2021
Q4 		$5K Sell
1,493
-19
-1% -$63 ﹤0.01% 4117
2021
Q3 		$5K Buy
1,512
+21
+1% +$74 ﹤0.01% 3977
2021
Q2 		$6K Sell
1,491
-21
-1% -$89 ﹤0.01% 3815
2021
Q1 		$8K Buy
1,512
+512
+51% +$4.14K ﹤0.01% 3567
2020
Q4 		$13K Hold
1,000
– – ﹤0.01% 2467
2020
Q3 		$10K Hold
1,000
– – ﹤0.01% 2294
2020
Q2 		$10K Buy
+1,000
New +$9.59K ﹤0.01% 2198
2019
Q1 		– Sell
-200
Closed -$3K – 1915
2018
Q4 		$3K Buy
+200
New +$2.76K ﹤0.01% 1456

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAPTRUST Financial Advisors's CNCE Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2022, closing a stake of 1,394 shares — an estimated $6K sold.

CAPTRUST Financial Advisors first reported a position in CNCE in Q4 2018 and held it in 10 quarters. The position peaked at $13K in Q4 2020. 80 funds tracked by Wall St. Rank hold CNCE as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1,394 Concert Pharmaceuticals, Inc. shares in Q3 2022, an estimated $6K.
  • CAPTRUST Financial Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q4 2018 and held it in 10 quarters.
  • CAPTRUST Financial Advisors's Concert Pharmaceuticals, Inc. position peaked at $13K in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.